Ropeginterferon alfa-2b <i>vs</i> standard therapy in polycythemia vera: A meta-analysis of efficacy and safety outcomes

RI offers superior hematologic and molecular responses compared to ST in PV but is associated with higher discontinuation rates due to AEs. Comparable thrombotic risk and reduced phlebotomy needs highlight its potential, though tolerability requires careful management. The high heterogeneity in certain outcomes and potential for publication bias warrant cautious interpretation of these findings. Further long-term studies are needed to optimize dosing and patient selection.

Authors

Institutions

Publication Details

Journal
World Journal of Clinical Oncology
Published
2025-10-24
DOI
https://doi.org/10.5306/wjco.v16.i10.112392
Citations
1
Primary Topic
Myeloproliferative Neoplasms: Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
1.63
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Ropeginterferon alfa-2b vs standard therapy in polycythemia vera: A meta-analysis of efficacy and safety outcomes

Naseem Salahuddin, Ali Sher, Mirza Muhammad Hadeed Khawar, S. C. Mani et al.
1 citations
World Journal of Clinical Oncology
Myeloproliferative Neoplasms: Diagnosis and Treatment
1.63
article

Ropeginterferon alfa-2b vs standard therapy in polycythemia vera: A meta-analysis of efficacy and safety outcomes

Naseem Salahuddin, Ali Sher, Mirza Muhammad Hadeed Khawar, S. C. Mani, Ashesh Kumar Das, Ajay Kumar Singh Rawat, M. B. Abdurrahman, Anu Gopinath, Shruti Manoj Mundada, Leo Tom, Farzana Shaju, Syeda Parsa, Mina Nan, Basel Al Khatib, Osama Taj
article en
1 citations

Abstract

RI offers superior hematologic and molecular responses compared to ST in PV but is associated with higher discontinuation rates due to AEs. Comparable thrombotic risk and reduced phlebotomy needs highlight its potential, though tolerability requires careful management. The high heterogeneity in certain outcomes and potential for publication bias warrant cautious interpretation of these findings. Further long-term studies are needed to optimize dosing and patient selection.

World Journal of Clinical OncologyVol. 16(10)
Services Institute of Medical Sciences (PK), Alfaisal University (SA), Gandhi Medical College & Hospital (IN), Gulf Medical University (AE), KPC Medical College and Hospital (IN), Trinity School of Medicine (VC), Civil Hospital Karachi (PK), Government of Kerala (IN), General Hospital Ernakulam (IN), Swami Rama Himalayan University (IN), Chandka Medical College (PK), Chittaranjan National Cancer Institute (IN), Narayana Health (IN), Government Medical College and Hospital (IN), Kharadar General Hospital (PK), Sree Gokulam Medical College and Research Foundation (IN), International University of Kyrgyzstan (KG), St. Vincent and the Grenadines Community College (VC), Health Action by People (IN), Capital Health (US), Government Medical College (IN), K S Hegde Medical Academy (IN)
Openalex Percentile: Top 12%
Myeloproliferative Neoplasms: Diagnosis and Treatment
1.63
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.